Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (May 2024)
35 slides from Pluri's investor presentation, May 2024
Slide 1: Investor Presentation
Nasdaq: PLUR TASE: PLUR.TA INVESTOR PRESENTATION May, 2024
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Solutions for Humanity's Greatest Challenges
AGING AND HEALTH CLIMATE CHANGE FOOD SECURITY SUSTAINABILITY SOLUTIONS FOR HUMANITY’S GREATEST CHALLENGES WE OFFER ROBUST CELL EXPANSION TECHNOLOGY PLATFORMS THAT CREATE NEW CELL-BASED SOLUTIONS. OUR TECHNOLOGY HAS THE POTENTIAL TO IMPROVE QUALITY OF LIFE AND MAKE OUR WORLD A BETTER PLACE. 3
Slide 4: Pluri at a Glance
PLURI AT A GLANCE COMPANY INDUSTRIES PARTNERS ● Nasdaq (PLUR), TASE (PLUR.TA) ● Cash & deposits: ~$31 million (as of December 31, 2023) ● Based in Israel with global presence, Regenerative medicine: Cultivated meat including in the USA and Europe cell therapies collaboration with Tnuva ● Rich IP por
Slide 5: Our Greatest Asset
OUR GREATEST ASSET The Pluri technology platforms leverage the basic building blocks of life—cells—to create medicine, food and cell-based materials that can change the course of human history. TECHNOLOGY ADVANTAGES Patented, proprietary 3D cell expansion technology to produce high-quality cells in
Slide 6: PluriMatrix™
PLURIMATRIX™ PluriMatrix™ is a breakthrough system for unprecedented industrial scale production of cell-based products PLURIMATRIX™ ADVANTAGES Significantly increases industrial scale production of cell-based products by using a packed-bed system Flexible production to power a range of cell-based p
Slide 7: Pluri's Cell Expansion Technology Platforms
PLURI’S CELL EXPANSION TECHNOLOGY PLATFORMS ONE TECHNOLOGY, MANY The potential applications SOLUTIONS are almost endless. Any industry that requires mass cell production can potentially benefit from Pluri’s patented technology. 7
Slide 8: Our Mission
OUR MISSION To leverage our advanced cell expansion platforms and position as a global leader in cell technology to develop, manufacture and market highly effective cell-based products and solutions that enhance global wellbeing and promote sustainability And many other industries… 8
Slide 9: PluriApps
PLURIAPPS Acute Radiation Osteoarthritis Cultivated Fish Cultivated Meat Cultivated Dairy Syndrome Cell-Based Coffee CDMO Cosmetics Biologics Biostimulants 9
Slide 10: Business Development Strategy
BUSINESS DEVELOPMENT STRATEGY Development and Partnerships that manufacturing of leverage Pluri’s innovative cell-based technology to meet cell- products using Pluri’s based manufacturing 3D cell expansion needs for a variety of technology industries 10
Slide 11: 11
11
Slide 12: Cell-Based Is Better
CELL-BASED IS BETTER Cell expansion technology produces mass scale, cost- effective food products in an efficient and sustainable manner ENVIRONMENTAL ETHICAL CONSUMER Fast growing industry: ● Uses significantly less land and ● Adheres to ethical animal ● Facilitates natural flavor water than conven
Slide 13: Landmark Collaboration for Cultivated Food Platform
LANDMARK COLLABORATION FOR CULTIVATED FOOD PLATFORM Ever After Foods is a joint venture to develop, manufacture and commercialize cell-based meat products for the food industry, announced in early 2022. Bringing sustainable, affordable cultivated food to consumers across the globe. COLLABORATION OF
Slide 14: Landmark Collaboration for Cultivated Food Platform
LANDMARK COLLABORATION FOR CULTIVATED FOOD PLATFORM • Tnuva invested $7.5 million in the Ever After Foods JV based on a $40 M pre-money valuation • Pluri granted to Ever After Foods an exclusive global royalty-bearing license to use its IP and expertise in the field of cultivated meat • Tnuva receiv
Slide 15: 15
15
Slide 16: The Evolution of Pluri's 3D Cell-Expansion Technology Platforms
THE EVOLUTION OF PLURI’S 3D CELL- EXPANSION TECHNOLOGY PLATFORMS ● Nearly 20 years of experience perfecting a manufacturing process to grow cells efficiently in mass quantities ● Developing an innovative line of placenta cell product candidates in regenerative medicine to treat unmet medical needs ●
Slide 17: Cell-Based Is Better
CELL-BASED IS BETTER Since 2003, Pluri has perfected methods to expand a single placenta cell into billions of distinct cells. ADVANTAGES OF CELL THERAPIES Cell therapy will take us SCIENTIFIC REACH FUTURE from chronic treatments and hospitalizations to ● Cell therapies encourage the body ● Cells fr
Slide 18: Advanced and Ongoing Clinical Studies
ADVANCED AND ONGOING CLINICAL STUDIES HAS change from week 6 Injured leg Phase I/II study of PLX-PAD for muscle injury following total hip replacement (N=20) 2KG difference from PLX-PAD demonstrated a significant increase in muscle strength & volume placebo at W26 (p=0.047) Phase III study of PLX-PA
Slide 19: PLX-R18 for Acute Radiation Syndrome (ARS)
PLX-R18 FOR ACUTE RADIATION SYNDROME (ARS) Significant increase in survival rate (68%) versus placebo (p<0.0001) ARS, also known as radiation sickness or radiation poisoning, is caused by exposure to high amounts of ionizing radiation, such as in nuclear reactor accidents or warfare Significant incr
Slide 20: Advanced and Ongoing Clinical Studies
ADVANCED AND ONGOING CLINICAL STUDIES PLX-R18 to stimulate the regeneration of damaged bone marrow following Hematopoietic Cell Transplantation (HCT) Positive Phase I results to demonstrate the safety and exploratory efficacy of PLX-R18 in humans reported March 2022 PLX-R18 reduced mortality from 29
Slide 21: Pluri Is Part of the PROTO Consortium
PLURI IS PART OF THE PROTO CONSORTIUM Phase I/IIa study of PLX-PAD for the treatment of mild to moderate knee osteoarthritis (OA) OA is one of the most common chronic articular diseases, global prevalence of 16% in the adult population1. Third most rapidly growing disease associated with disability2
Slide 22: Unlocking the Power of Immunotherapy
UNLOCKING THE POWER OF IMMUNOTHERAPY Immunotherapy is treatment that uses a person's own immune system to fight illness. In recent years, the field of this innovative treatment in general, and CAR-T in particular, has been gaining momentum for the treatment of cancer as well as viral infection and a
Slide 23: Pluri's Placental Allogeneic MAIT Platform
PLURI’S PLACENTAL ALLOGENEIC MAIT PLATFORM Pluri’s Mucosal-Associated Invariant T cells (MAIT) are unconventional immune cells derived from the human placenta. MAIT cells enable the CAR (Chimeric Antigen Receptor) to reach the tumor, potentially leading to better infiltration and efficacy. BENEFITS
Slide 24: CDMO
e e pluricdma
Slide 25: Pluri's Contract Development Manufacturing Organization
PLURI’S CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATION At PluriCDMO we work with our partners from early preclinical development to EXPERTISE EXPERIENCE FACILITY & LOGISTICS commercialization, with a • Deep process and analytical • Pluri’s team is experienced • Reliable logistics links and developm
Slide 26: Facility Overview
FACILITY OVERVIEW • With more than 15 years of GMP manufacturing expertise, Pluri is leveraging its skilled team, 4,400m² facility and logistics capabilities for cell therapy CDMO clients • GMP manufacturing facility compliant to Europe, USA and Israel standards o Local presence in Europe and USA fo
Slide 27: QC & Development Support, Technology & Process Capabilities
QC & DEVELOPMENT SUPPORT, TECHNOLOGY & PROCESS CAPABILITIES QUALITY COMPLIANCE TECHNOLOGY & PROCESS • Comprehensive Quality Management System • Allogeneic and autologous manufacturing • Monitoring, testing, product release, review and • Cell therapy types approval performed by an experienced staff o
Slide 28: Agtech
agtech cdmo 28
Slide 29: Cell-Based Is Better
CELL-BASED IS BETTER Reshaping the agricultural landscape and redefining the possibilities of ENVIRONMENT PRODUCT COST sustainable crop ● Safer and more efficient ● Pioneering work in cell ● Enhances agricultural production sustainability and productivity platform for producing a expansion technolog
Slide 30: The Coffee Crisis
THE COFFEE CRISIS CLIMATE CHANGE • Global coffee production will decrease by half in the next 30 years due to global warming PRICE INSTABILITY • US coffee import prices have risen by over 65% • Prices changed from 390 cents per kg to 624 and back to 419 cents per kg (2009-2023) LAND SHORTAGE • Land
Slide 31: Pluri's Cell-Based Coffee
PLURI’S CELL-BASED COFFEE PATENTED SUSTAINABLE COFFEE COFFEE CELL TECH Pioneering production 3D plant cell cultivation, for a sustainable and license to use Pluri’s IP ethical alternative and know-how ECO-EFFICIENT EXPERIENCE MASS SCALE PRODUCTION Two decades of experience and a Reducing carbon prof
Slide 32: Significant Support from Leading Organizations
SIGNIFICANT SUPPORT FROM LEADING ORGANIZATIONS REGULATORY SCIENTIFIC COLLABORATIONS AND PARTNERING FUNDING 32
Slide 33: Commitment to Excellence
COMMITMENT TO EXCELLENCE Yaky Yanay Chen Franco-Yehuda Dr. Nitsan Halevy, MD Lior Raviv Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Medical Officer Chief Technology Officer Chief Commercial Officer Dr. Arthur Machlenkin, PhD Efrat Livne-Hadass Orly Amiran Efrat Kaduri John Dvor Chie
Slide 34: Making a Positive Impact
MAKING A POSITIVE IMPACT* Healthcare Foodtech Work & Community Reduced Environmental Footprint Male 3% Up to Up to 93% Male Disabled Female 37% Female 32% 11% 3% 95% 78% Decrease 63% 68% Employees Less land Less water Air Pollution Employees Management Minority Disabled As the average age increases,
Slide 35: The Promise & the Opportunity
THE PROMISE & THE OPPORTUNITY Pluri’s cell-expansion technology will touch and improve every aspect of our lives. Promoting sustainability, wellbeing and improving quality of life. For every one of us. Individually. And for all of us, as a society. Together. For further information contact: investor